Table 6.

Recent US cooperative group experience in frontline MCL trials

Trial	n	Median age	MIPI (%)	3 years	3 years
			Low/Int/High	PFS (%)	OS (%)
ECOG 1405	75*	62	41/38/22	72	86
SWOG 012325	49	57	55/31/14	66	81
CALGB 5990923	78	57	53/31/15	63	83

CALGB, Cancer and Leukemia Group B; int, intermediate.

^*ASCT patients (n = 22) censored at time of transplant.